Article written by Bruce Sylvester. Researchers report that both single and dual immunotherapy improve overall survival among patients with advanced esophageal squamous cell carcinoma, particularly those positive for… read more.
Immunotherapy with pembrolizumab after surgery significantly improves disease-free survival among patients with the most prevalent form of kidney cancer, clear-cell renal carcinoma. Researchers reported this finding on June… read more.
Article written by Bruce Sylvester. When treated with adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy, patients with high-risk, HER2-negative early breast cancer and… read more.
Seagen Inc. announced that improvements in overall survival (OS) and progression-free survival (PFS) were maintained with long-term follow up from the pivotal HER2CLIMB trial evaluating the addition of… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
